课题基金 / 基金详情

CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIA

CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIA
精神分裂症的长期安非他明给药
批准号：
3759475
负责人：
L B BIGELOW
金额：
$0.0万
依托单位：
NATIONAL INSTITUTE OF MENTAL HEALTH
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3759475
关键词：
amphetamines combination chemotherapy dopamine receptor human subject human therapy evaluation interview neuropharmacologic agent psychosis schizophrenia sign /symptom

项目摘要

项目成果

L B BIGELOW的其他基金

相似基金

相关文献

中文摘要
翻译
慢性精神分裂症的缺陷症状尤其具有抵抗力
英文摘要
Deficit symptoms in chronic schizophrenia are particularly resistant to treatment. Indeed, the most common drugs used to treat schizophrenia, the neuroleptics, many indirectly intensify deficit symptoms by virtue of their non-specific blockade of all the subtypes of dopamine receptors. This study tests the hypothesis that the coadministration to schizophrenics "protected" by neuroleptic might reduce deficit symptoms without exacerbating psychotic symptoms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF MIGRAINE WITH ANIONIC POLYELECTROLYTES
PENTOSAN POLYSULFATE AS PROPHYLAXIS FOR MIGRAINE
ANTI-HIV POTENTIAL OF PENTOSAN POLYSULFATE
THE BRIEF PSYCHIATRIC RATING SCALE AS A WARD DAILY RATING SYSTEM
海外基金